Tag:
actavis
Latest Headlines
Latest Headlines
The top M&A dealmakers in biopharma
Step back and look at the trend in biopharma M&A and you'll find less money than you would have seen on the table last year. Read the report on this year's dealmaking climate >>
Actavis eyes fast-growing biosimilar market
With a deal on the table to buy up a 51 percent stake in Poland's Bioton, Actavis says it wants to use the move as a springboard into biosimilars. Like a slate of biopharma companies, the Icelandic
Actavis to buy Abrika Pharma in $238M deal
Iceland's generic drug maker Actavis has agreed to buy Abrika Pharmaceuticals in the U.S. for up to $238.5 million. Actavis will make an initial payment of $110 million in cash and up to $125 million based on its performance over the next three years. Actavis says the deal will make it a leader in the U.S. for controlled-release drugs. The Icelandic company recently lost a bidding war with Barr for Croatia's Pliva.
- here's the …
SPOTLIGHT: Actavis buys ZiO Zdorovje for $60M
Generic drug maker Actavis has announced that it has acquired a 51 percent controlling interest in Russian manufacturer ZiO Zdorovje. The total deal is for $60 million, and Actavis says that it hopes the investment will give it a foothold in the expanding Russian generics market. "We believe that the combination of our local manufacturing expertise with Actavis' extensive product portfolio will significantly enhance the growth prospects for both businesses and we are very excited …
Press Release: Actavis expands presence in Russia
Press Release: Actavis expands presence in Russia
Barr gains majority of Pliva shares
Barr Pharmaceuticals would appear to have won the battle for Croatia's Pliva with its announcement that it has acquired more than 70 percent of the drug maker's stock. Barr had been in a bidding war with Actavis for control of Pliva. If Barr completes the deal, which seems likely, it will create the world's third largest generic drug maker.
- Here's the article from the International Herald Tribune
SPOTLIGHT: Actavis receives warning letter
The FDA has issued a warning letter regarding Actavis' manufacturing facility in Little Falls, NJ. The agency has questioned its reporting of adverse medical events and raised questions regarding the marketing status of older products. No new products will be made there until the agency's concerns are satisfied. Report
Actavis ups ante in bidding war for Pliva
Iceland's Actavis has upped its bid to acquire Croatia's Pliva to $139 a share, surpassing the latest offer from Barr. But analysts say the bidding war isn't over yet. They're waiting to see how Barr reacts to this latest bid and many expect yet another higher bid to hit the table. The winner in the bidding war for Pliva will create the world's third largest generic drug maker, behind Teva and Novartis.
- see the AFX report on Actavis' bid
ALSO NOTED: Xyotax trial indicates efficacy; Wyeth encouraged by FDA meeting cancellation;and much more...
> Cell Therapeutics reported that more than half of the patients in a small Phase I dosing study of its cancer therapy Xyotax saw tumors shrink or disappear. Of 12 patients with cancer limited to a local region, four saw tumors disappear and seven had their tumors shrink by more than 50 percent. Report
> Wyeth says its encouraged by a recent decision by the FDA to cancel an advisory committee meeting to …
ALSO NOTED: FDA delays Adderall decision;Actavis raises Pliva bid; and much more...
> Shire says that the FDA has told the company that it hasn't been able to make a decision on its concerns that copycat versions of Adderall XR are too easy to produce. Shire wants the agency to require more rigorous bioequivalence testing. Report
> Iceland's Actavis has raised its bid for Pliva by 11 percent. …
